{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:38:21Z","timestamp":1793943501850,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rivaroxaban is a direct oral anticoagulant medication that has been found to be beneficial for the management of thromboembolic events linked to the Corona virus disease 2019 (COVID-19) pandemic, which has resulted in more than 6\u00a0million deaths worldwide. Hence, a sensitive, selective, and green bioanalytically validated method was developed using RP-HPLC coupled with DAD for the simultaneous determination of rivaroxaban in human plasma, and two co-administered drugs, namely, paracetamol, an analgesic, and ceftriaxone, an antibiotic, that are used in the management of COVID-19. An Exsil 100 ODS C18 column (250\u2009\u00d7\u20094.6\u00a0mm, 5\u00a0\u03bcm) was used as the stationary phase, and acetonitrile: water: methanol at a ratio of 60:30:10 (v\/v\/v) was used in isocratic mode as the mobile phase with a flow rate of 0.7\u00a0ml\/min. The method was validated over a concentration range of 0.1\u201310.0\u00a0\u00b5g\/mL for rivaroxaban, and 1.0\u201315.0\u00a0\u00b5g\/mL for paracetamol and ceftriaxone. The lower limits of detection (LLODs) were found to be 0.03, 0.32, and 0.32\u00a0\u00b5g\/ml for rivaroxaban, paracetamol, and ceftriaxone, respectively. Moreover, the lower limits of quantitation (LLOQs) were found to be 0.1, 0.96, and 0.98\u00a0\u00b5g\/ml. The developed method showed excellent accuracy and precision for the determination of the aforementioned drugs. Four metrics were used to evaluate the greenness of the developed method. The results revealed that the suggested method is green, with values of 81 and 0.6 for the analytical eco-scale and analytical greenness assessment (AGREE), respectively.<\/jats:p>","DOI":"10.1038\/s41598-024-75729-y","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T08:43:52Z","timestamp":1730105032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A bioanalytically validated RP-HPLC method for simultaneous quantification of rivaroxaban, paracetamol, and ceftriaxone in human plasma: a combination used for COVID-19 management"],"prefix":"10.1038","volume":"14","author":[{"given":"Reham A.","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam F.","family":"Ayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna A.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossra A.","family":"Trabik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"5","key":"75729_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jiph.2020.03.019","volume":"13","author":"H Harapan","year":"2020","unstructured":"Harapan, H., Itoh, N.,Yufika,A., et al. Coronavirus disease 2019 (COVID\u201319): A literature review. J. Infect. Public Health 13(5), 667\u2013673. https:\/\/doi.org\/10.1016\/j.jiph.2020.03.019 (2020).","journal-title":"J. Infect. Public Health"},{"issue":"20","key":"75729_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40560-021-00535-x","volume":"9","author":"J Ng","year":"2021","unstructured":"Ng, J., Liang, Z. and Choong, A. The incidence of pulmonary thromboembolism in COVID\u201319 patients admitted to the intensive care unit: a meta-analysis and meta-regression of observational studies. J. Intensive Care 9(20), 20. https:\/\/doi.org\/10.1186\/s40560-021-00535-x (2021).","journal-title":"Journal of Intensive Care"},{"issue":"23","key":"75729_CR3","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","volume":"75","author":"B Bikdeli","year":"2020","unstructured":"Bikdeli, B., Madhavan, M., Jimenez, D., et al. COVID\u201319 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review.  J. Am. Coll. Cardiol. 75 (23), 2950\u20132973. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.031 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"75729_CR4","unstructured":"COVID\u201319 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID\u201319) Treatment Guidelines. National Institutes of Health."},{"key":"75729_CR5","doi-asserted-by":"publisher","unstructured":"Leal, N., Yu, Y., Chen, Y., et al. Paracetamol is associated with a lower risk of COVID\u201319 infection and decreased ACE2 protein expression: A retrospective analysis. COVID 1, 218\u2013229. https:\/\/doi.org\/10.3390\/covid1010018 (2021).","DOI":"10.3390\/covid1010018"},{"issue":"1","key":"75729_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41182-021-00344-w","volume":"49","author":"Y Adebisi","year":"2021","unstructured":"Adebisi, Y., Jimoh, N., Ogunkola, I., et al., The use of antibiotics in COVID\u201319 management: a rapid review of national treatment guidelines in 10 African countries. Trop. Med. Health 49(1), 51. https:\/\/doi.org\/10.1186\/s41182-021-00344-w (2021).","journal-title":"Trop. Med. Health"},{"issue":"8","key":"75729_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2157-7064.1000202","volume":"4","author":"I Lories","year":"2013","unstructured":"Lories, I., Mostafa, A. and Girges,M., High performance liquid chromatography, TLC densitometry, first derivative and first derivative ratio spectrophotometry for determination of rivaroxaban and its alkaline degradates in bulk powder and its tablets. J. Chromatogr. Sep. Tech.., 4(8), 1\u20136. https:\/\/doi.org\/10.4172\/2157-7064.1000202 (2013).","journal-title":"J. Chromatogr. Sep. Tech."},{"issue":"10","key":"75729_CR8","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/jth.12702","volume":"12","author":"E Schmitz","year":"2014","unstructured":"Schmitz, E., Boonen, K., van den Heuvel, D., et al., Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography \u2013 tandem mass spectrometry (UPLC\u2010MS\/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.  J. Thromb. Haemost. 12(10), 1636\u20131646. https:\/\/doi.org\/10.1111\/jth.12702 (2014).","journal-title":"J. Thromb. Haemost."},{"key":"75729_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11239-014-1121-2","volume":"39","author":"M Iqbal","year":"2015","unstructured":"Iqbal, M., Khalil, N., Imam, F. et al., A validated high-throughput UHPLC-MS\/MS assay for accurate determination of rivaroxaban in plasma sample.  J. Thromb. Haemost. 39, 79\u201388. DOI: https:\/\/doi.org\/10.1007\/s11239-014-1121-2 (2015).","journal-title":"J. Thromb. Haemost."},{"issue":"1\u20132","key":"75729_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jchromb.2008.07.015","volume":"872","author":"G Rohde","year":"2008","unstructured":"Rohde, G., Determination of rivaroxaban \u2013 a novel, oral, direct factor xa inhibitor \u2013 in human plasma by high-performance liquid chromatography\u2013tandem mass spectrometry. J. Chromatogr. B, 872(1\u20132), 43\u201350. DOI: https:\/\/doi.org\/10.1016\/j.jchromb.2008.07.015 (2008).","journal-title":"Journal of Chromatography B"},{"key":"75729_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jpba.2014.08.011","volume":"100","author":"M Korostelev","year":"2014","unstructured":"Korostelev, M., Bihan, K., Ferreol, L., et al., Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography\u2013tandem mass spectrometry.  J. Pharm. Biomed. Anal. 100, 230\u2013235. https:\/\/doi.org\/10.1016\/j.jpba.2014.08.011 (2014).","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"75729_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/chromsci\/bmv135","volume":"54","author":"M \u00c7elebier","year":"2016","unstructured":"\u00c7elebier, M., Re\u00e7ber, T., Ko\u00e7ak, E., et al., Determination of rivaroxaban in human plasma by solid-phase extraction\u2013high performance liquid chromatography.J. Chromatogr. Sci., 54(2), 216\u2013220. https:\/\/doi.org\/10.1093\/chromsci\/bmv135 (2016).","journal-title":"J. Chromatogr. Sci."},{"issue":"8","key":"75729_CR13","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/0731-7085(95)01303-3","volume":"13","author":"S Al-Obaidy","year":"1995","unstructured":"Al-Obaidy, S., Li-Wan-Po, A., McKiernan, P., et al., Assay of paracetamol and its metabolites in urine, plasma and saliva of children with chronic liver disease. J. Pharm. Biomed. Anal. 13(8), 1033\u20131039. https:\/\/doi.org\/10.1016\/0731-7085(95)01303-3 (1995).","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"75729_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/chromsci\/40.2.97","volume":"40","author":"H Senyuva","year":"2002","unstructured":"Senyuva, H. and Ozden, T., Simultaneous high-performance liquid chromatographic determination of paracetamol, phenylephrine HCl, and chlorpheniramine maleate in pharmaceutical dosage forms. J. Chromatogr. Sci. 40(2), 97\u2013100. https:\/\/doi.org\/10.1093\/chromsci\/40.2.97 (2002).","journal-title":"J. Chromatogr. Sci."},{"key":"75729_CR15","doi-asserted-by":"publisher","unstructured":"Nagaralli, B., Jaldappa, S., Babu, G., et al., Liquid chromatographic determination of ceterizine hydrochloride and paracetamol in human plasma and pharmaceutical formulations. Anal. Technol. Biomed Life Sci. 798(1), 49\u201354. DOI: https:\/\/doi.org\/10.1016\/j.jchromb.2003.08.048 (2003).","DOI":"10.1016\/j.jchromb.2003.08.048"},{"issue":"4","key":"75729_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5530\/ijper.47.4.9","volume":"47","author":"K Delvadiya","year":"2014","unstructured":"Delvadiya, K., Kapara, P., Kimbahune, R., et al., High-performance liquid chromatographic determination of paracetamol, propyphenazone, and caffeine in pharmaceutical formulations Indian. J. Pharm. Educ. Res. 47(4), 65\u201372. https:\/\/doi.org\/10.5530\/ijper.47.4.9 (2014).","journal-title":"J. Pharm. Educ. Res."},{"key":"75729_CR17","doi-asserted-by":"publisher","unstructured":"Kam, R., Chan, M., Ghose, A., et al., Quantitation of paracetamol by liquid chromatography-mass spectrometry in human plasma in support of clinical trial.  Future Sci. OA 4 (8), FSO331. https:\/\/doi.org\/10.4155\/fsoa-2018-0039 (2018).","DOI":"10.4155\/fsoa-2018-0039"},{"key":"75729_CR18","doi-asserted-by":"publisher","unstructured":"Dargue, R., Grant, I., Nye, L., et al., The analysis of acetaminophen (paracetamol) and seven metabolites in rat, pig and human plasma by U(H)PLC-MS. Bioanalysis 12(7), 485\u2013500. https:\/\/doi.org\/10.4155\/bio-2020-0015 (2020).","DOI":"10.4155\/bio-2020-0015"},{"issue":"4","key":"75729_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0731-7085(88)80006-2","volume":"6","author":"F Demotes-Mainard","year":"1988","unstructured":"Demotes-Mainard, F., Vin\u00e7on, G., Jarry, C., et al., Micromethod for determination of ceftriaxone in plasma and urine by high-performance liquid chromatography.  J. Pharm. Biomed. Anal., 6(4), 407\u2013413. https:\/\/doi.org\/10.1016\/0731-7085(88)80006-2 (1988).","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"4","key":"75729_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0731-7085(98)00274-X","volume":"18","author":"S Eric-Jovanovic","year":"1998","unstructured":"Eric-Jovanovic, S., Agbaba, D., Zivanov-Stakic, D,. et al. HPTLC determination of ceftriaxone, cefixime and cefotaxime in dosage forms. J. Pharm. Biomed. Anal., 18(4), 893\u2013898. https:\/\/doi.org\/10.1016\/S0731-7085(98)00274-X (1998).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"75729_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jchromb.2019.06.008","volume":"1124","author":"A Kotani","year":"2019","unstructured":"Kotani, A., Hirai, J., Hamada, Y., et al., Determination of ceftriaxone concentration in human cerebrospinal fluid by high-performance liquid chromatography with UV detection. J. Chromatogr. B 1124, 161\u2013164. https:\/\/doi.org\/10.1016\/j.jchromb.2019.06.008 (2019).","journal-title":"J. Chromatogr. B"},{"key":"75729_CR22","doi-asserted-by":"publisher","first-page":"106372","DOI":"10.1016\/j.microc.2021.106372","volume":"168","author":"S Narimani","year":"2021","unstructured":"Narimani, S. and Samadi, N., Rapid trace analysis of ceftriaxone using new fluorescent carbon dots as a highly sensitive turn-off nanoprobe. Microchem. J. 168, 106372. https:\/\/doi.org\/10.1016\/j.microc.2021.106372 (2021).","journal-title":"Microchem. J."},{"issue":"5","key":"75729_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1039\/D2AY02016E","volume":"15","author":"C Xiao","year":"2023","unstructured":"Xiao, C., Zhang, X., Wang, W., et al., Developing an improved UHPLC method for impurity profile analysis of ceftriaxone using analytical quality by design. Anal. Methods 15(5), 639\u2013647. DOI: https:\/\/doi.org\/10.1039\/D2AY02016E (2023).","journal-title":"Anal. Methods"},{"key":"75729_CR24","unstructured":"Bioanalytical Method Validation Guidance for Industry. Food and Drug Administration, HHS., 83(99), 23690\u201323691 (2018)."},{"issue":"3","key":"75729_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.55730\/1300-0527.3566","volume":"47","author":"F Selimo\u011flu","year":"2023","unstructured":"Selimo\u011flu, F. and Pinarcik, N., Spectrophotometric quantification of paracetamol and tramadol hydrochloride by chemometric calibration methods. Turk. J. Chem. 47(3), 633\u2013645. https:\/\/doi.org\/10.55730\/1300-0527.3566 (2023).","journal-title":"Turk. J. Chem."},{"issue":"5","key":"75729_CR26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/molecules23051065","volume":"23","author":"M Yabr\u00e9","year":"2018","unstructured":"Yabr\u00e9, M., Ferey, L., Som\u00e9, I., et al., Greening reversed-phase liquid chromatography methods using alternative solvents for pharmaceutical analysis. Molecules 23(5), 1065. https:\/\/doi.org\/10.3390\/molecules23051065 (2018).","journal-title":"Molecules"},{"issue":"1","key":"75729_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13065-019-0618-3","volume":"13","author":"C El-Maraghy","year":"2019","unstructured":"El-Maraghy, C. and Lamie, N., Three smart spectrophotometric methods for resolution of severely overlapped binary mixture of Ibuprofen and Paracetamol in pharmaceutical dosage form. BMC Chem. 13(1), 99. DOI: https:\/\/doi.org\/10.1186\/s13065-019-0618-3 (2019).","journal-title":"BMC Chem."},{"issue":"2","key":"75729_CR28","first-page":"38","volume":"8","author":"S Kodipyaka","year":"2020","unstructured":"Kodipyaka, S., Pola, R., Yenumula, P., et al., Development and validation of bio-analytical method for the quantitative estimation of rivaroxaban by using UV spectrophotometry. World J. Pharm. Sci. 8(2), 38\u201343 (2020).","journal-title":"World J. Pharm. Sci."},{"key":"75729_CR29","doi-asserted-by":"publisher","unstructured":"Dew, L., Djoko Wahyono, D., Puspitasari, I., et al., Validation of simple spectrophotometric method for determination of ceftriaxone in human plasma. Int. J. Res. Pharm. Sci 11((SPL 4)), 1645\u2013164.9. https:\/\/doi.org\/10.26452\/ijrps.v11iSPL4.4351 (2020).","DOI":"10.26452\/ijrps.v11iSPL4.4351"},{"issue":"1","key":"75729_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0378-5173(99)00309-9","volume":"193","author":"T Tsai","year":"1999","unstructured":"Tsai, T., Cheng, F., Hung, L., et al., Determination of unbound ceftriaxone in rat blood by on-line microdialysis and microbore liquid chromatography. Int. J. Pharm., 193(1), 21\u201326. https:\/\/doi.org\/10.1016\/S0378-5173(99)00309-9 (1999).","journal-title":"International Journal of Pharmaceutics"},{"key":"75729_CR31","volume-title":"Validation of Chromatographic Methods","author":"R Guidance","year":"1994","unstructured":"Guidance, R., Validation of Chromatographic Methods. Center for Drug Evaluation and Research (CDER), 1994. 2","edition":"2"},{"key":"75729_CR32","doi-asserted-by":"publisher","first-page":"107242","DOI":"10.1016\/j.microc.2022.107242","volume":"176","author":"A Ahmed","year":"2022","unstructured":"Ahmed, A., Gamal, M., Naguib, I., et al., Environmental impact of the reported chromatographic methods for the determination of the first FDA-Approved therapy for COVID\u201319 Patients, Remdesivir: A comparative study. Microchem. J. 176, 107242. https:\/\/doi.org\/10.1016\/j.microc.2022.107242 (2022).","journal-title":"Microchemical Journal"},{"issue":"6","key":"75729_CR33","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1021\/cr068359e","volume":"107","author":"L Keith","year":"2007","unstructured":"Keith, L., Gron, L. and Young, J., Green analytical methodologies.  Chem. Rev. 107(6), 2695\u20132708. https:\/\/doi.org\/10.1021\/cr068359e (2007).","journal-title":"Chem. Rev."},{"key":"75729_CR34","unstructured":"Code of Federal Regulations, Protection of Environment, Identification and Listing of Hazardous Waste, Environmental Protection Agency (EPA) ( 2016)."},{"key":"75729_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J P\u0142otka-Wasylka","year":"2018","unstructured":"P\u0142otka-Wasylka, J., A new tool for the evaluation of the analytical procedure: Green Analytical Procedure Index. Talanta 181, 204\u2013209. https:\/\/doi.org\/10.1016\/j.talanta.2018.01.013 (2018).","journal-title":"Talanta"},{"key":"75729_CR36","doi-asserted-by":"publisher","unstructured":"Trabik, Y., Ismail, R., Farid, M., et al. Microfabricated potentiometric sensor based on a carbon nanotube transducer layer for selective Bosentan determination. Rev. Anal. Chem., 43(1). https:\/\/doi.org\/10.1515\/revac-2023-0071 (2024).","DOI":"10.1515\/revac-2023-0071"},{"issue":"14","key":"75729_CR37","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. and Tobiszewski, M., AGREE\u2014Analytical GREEnness metric approach and software. Anal. Chem., 92(14), 10076\u201310082. https:\/\/doi.org\/10.1021\/acs.analchem.0c01887 (2020).","journal-title":"Anal. Chem."},{"issue":"3","key":"75729_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1039\/D0AY02169E","volume":"13","author":"M Gamal","year":"2021","unstructured":"Gamal, M., Naguib, A., Pada, D., et al., Comparative study of four greenness assessment tools for selection of greenest analytical method for assay of hyoscine N-butyl bromide. Anal. Methods 13(3), 369\u2013380. DOI: https:\/\/doi.org\/10.1039\/D0AY02169E (2024).","journal-title":"Anal. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75729-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75729-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75729-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:05:14Z","timestamp":1730365514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75729-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75729"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75729-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25693"}}